CG Invites Co., Ltd. (KOSDAQ:083790)

Market Cap	103.12B -41.9%
Revenue (ttm)	18.12B +225.1%
Net Income	-49.68B
EPS	-647.58
Shares Out	76.89M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	191,420
Average Volume	244,497
Open	1,341.00
Previous Close	1,341.00
Day's Range	1,268.00 - 1,348.00
52-Week Range	1,171.00 - 2,625.00
Beta	0.15
RSI	54.42
Earnings Date	Mar 19, 2026

About CG Invites

CG Invites Co., Ltd., a biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea. It offers Acelex (polmacoxib), an anti-inflammatory and pain relief drug, as well as CG-650, an anti-inflammatory drug, currently under phase 1 stage for the treatment of osteoarthritis; CG-651, an anti-inflammatory drug, currently under phase 1 stage for the treatment of neuropathic pain; and CG-652, an anti-inflammatory drug, currently under phase 1 stage for the treatment of rheumatoid arthritis. The compan...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 105
• Stock Exchange: KOSDAQ
• Ticker Symbol: 083790

Financial Performance

In 2024, CG Invites's revenue was 7.25 billion, an increase of 48.67% compared to the previous year's 4.88 billion. Losses were -51.54 billion, 5.36% more than in 2023.